Selank Explained: How It Works and Who It's For

Selank at a glance:

• Drug class: Neuropeptide / nootropic
• Route: intranasal or subcutaneous (research and ex-US clinical use)
• Typical frequency: varies
• Half-life: typically minutes systemically; intranasal formulations target CNS

If you're trying to figure out whether Selank is right for you — or for someone you care about — the right starting point is the basic biology. Selank is a neuropeptide / nootropic. Reported cognitive, mood, or neuroprotective effects in non-US clinical and preclinical studies.

What is Selank?

Nootropic peptides act on BDNF, NGF, or neurotransmitter systems to influence memory, mood, and neuroprotection.

There is no single FDA-licensed manufacturer of Selank for human therapeutic use. Material in the research and grey markets is supplied by various unregulated sources, which raises real questions about purity and dosing accuracy. Selank is not currently approved by the FDA for general human use. Available evidence comes from early-phase clinical work. We do not endorse self-administration of unapproved compounds.

The drug class neuropeptide / nootropic works by targeting specific receptor pathways. Here's what to expect.

How Selank Works in the Body

Nootropic peptides act on BDNF, NGF, or neurotransmitter systems to influence memory, mood, and neuroprotection. The receptor target — compound-specific — drives the downstream effects users care about: reported cognitive, mood, or neuroprotective effects in non-us clinical and preclinical studies.

The pharmacokinetics matter for daily use. Selank has a half-life of typically minutes systemically; intranasal formulations target CNS, which determines how often it is dosed. The standard route of administration is intranasal or subcutaneous (research and ex-US clinical use), and the typical schedule is varies.

For more detail on the underlying biology, see our breakdown of how Selank works.

Who Uses Selank?

Selank is most relevant for people whose situation maps to its approved indications: several are approved in Russia and Eastern Europe for stroke recovery, anxiety, or cognitive impairment; not FDA-approved.

People who should avoid Selank include those with the following:

• allergy to the active ingredient or any excipient
• pregnancy or breastfeeding (per label)
• conditions specifically called out in the prescribing information

Common and Serious Side Effects

The most commonly reported side effects of Selank include:

• mild local reactions

Serious risks — uncommon but worth knowing — include:

• limited long-term data outside short-term ex-US use

We have a more detailed breakdown in our Selank side-effects guide.

Selank vs Alternatives

Evidence-based US-approved cognitive and mood therapies should be considered first-line. If you are weighing Selank against another option, our comparison pages include Selank Side Effects Decoded: What's Normal vs. What Isn't, Real Selank Results: What 6 and 12 Months Actually Look Like, Selank Cost in 2026: What You'll Actually Pay (Real Numbers).

Bottom Line

Selank delivers what its label says it delivers. The case for it (or against it) comes down to your specific situation, not abstract comparisons. Evidence remains preliminary; we recommend caution and clinician oversight. If you are considering Selank, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• Selank Side Effects Decoded: What's Normal vs. What Isn't
• Real Selank Results: What 6 and 12 Months Actually Look Like
• Selank Cost in 2026: What You'll Actually Pay (Real Numbers)
• Selank Cycles Explained: Where the Evidence Stops
• Is Noopept Right for You? An Evidence-Based Breakdown
• Noopept Side Effects: 7 Things to Watch For (and How to Manage Them)

Sources

• Kozlovskaya MM et al. Selank and Short Peptides of the Glyprolines Family — Anxiolytic and Nootropic Activity. Eksp Klin Farmakol 2003;66:43.
• Muresanu DF et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled Trial. Stroke 2016;47:151.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.